- cafead   May 06, 2020 at 12:32: PM
via While Roche awaits results from a pair of large Phase III trials, the Swiss pharma is touting another round of data from a smaller study on its wet macular degeneration (nAMD) bispecific antibody, faricimab.
article source
article source